BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Maquet Cardiovascular LLC Receives FDA 510(k) Clearance and CE Mark Approval for AIR-BAND™ Radial Compression Device


4/11/2013 6:50:11 AM

WAYNE, N.J., April 11, 2013 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and European CE mark approval for its new AIR-BANDRadial Compression Device. Indicated to assist hemostasis of the radial artery after a transradial procedure, the device is designed to compress the radial artery puncture site while maintaining site visibility and a secure fit around the wrist. AIR-BAND will be commercially available in the European Union later this month and in the United States in April.

"We have found that AIR-BAND is easy to use, reliable and effective in achieving hemostasis following radially accessed coronary catheterization procedures," said Christian Valina, M.D., interventional cardiologist at the University Heart Centre of Bad Krozingen in Germany. "My colleagues and I were impressed by the secure fit around the wrist that the adhesive band provides. We believe that AIR-BAND represents important progress towards ensuring patient safety and comfort during these important procedures." Similar positive feedback has also been received from other sites in the EU and USA.

"Drawing on our significant experience in hemostasis management, we designed AIR-BAND to provide all the valued benefits of our SAFEGUARD® Pressure Assisted Devicewhich assists in obtaining and maintaining hemostasis after a femoral procedureand applied our knowledge to a radial application," said Christian Keller, President and Chief Executive Officer of MAQUET Cardiovascular. "Both devices simplify hemostasis management by delivering hands-free adjustable pressure, offering simple application and removal, and providing clear site visibility and assessment without compromising patient comfort, which is a priority for us."

About AIR-BAND
AIR-BAND is a 26-cm long, latex-free, self-adhesive wristband with a clear window and bulb that facilitate visualization of the puncture site. A luer valve on the end of the clear fill tube enables any standard syringe to be connected to inflate and deflate the bulb with air to provide compression of the radial puncture site.

With its textile wristband, AIR-BAND contributes to patient comfort, as it neither cuts into the skin nor has protruding plastic parts. The adhesive enables a secure fit around all patient wrists, avoiding movement and dislocation. Both the size and shape of AIR-BAND's inflatable bulb minimize the compression risk to surrounding nerve structures or areas other than the radial puncture site. The standard luer valve allows easy inflation and deflation with any standard luer syringe.

About MAQUET
MAQUET, a trusted partner for hospitals and physicians for over 175 years, is the global leader in providing medical systems that meet the needs of the most medically challenging patients, while exceeding the expectations of the hospital teams that care for them. MAQUET designs, develops and distributes innovative therapy solutions and infrastructure capabilities for high-acuity areas within the hospital including the operating room (OR), hybrid OR/cath lab and intensive care unit (ICU) as well as intra and inter hospital patient transport.

Headquartered in Rastatt, Germany, MAQUET is the largest subsidiary of the publicly listed Getinge Group AB of Sweden. MAQUET generated about 1.5 billion Euros in 2012, representing more than half of the Getinge Group's annual revenue of 2.7 billion Euros. MAQUET has 6,300 employees in 45 international sales and service organizations, as well as a network of more than 300 sales representatives. For more information please visit www.maquet.com.

MAQUET The Gold Standard
www.maquet.com
www.getingegroup.com

SOURCE MAQUET Cardiovascular LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES